Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization

• Published in: Antimicrobial agents and chemotherapy Vol. 59; no. 1; pp. 570 - 578
• Main Authors: Merchan, L Marcela, Hassan, Hazem E, Terrin, Michael L, Waites, Ken B, Kaufman, David A, Ambalavanan, Namasivayam, Donohue, Pamela, Dulkerian, Susan J, Schelonka, Robert, Magder, Laurence S, Shukla, Sagar, Eddington, Natalie D, Viscardi, Rose M
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.01.2015
• Subjects: Administration, Intravenous; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - pharmacokinetics; Anti-Bacterial Agents - therapeutic use; Azithromycin; Azithromycin - administration & dosage; Azithromycin - adverse effects; Azithromycin - pharmacokinetics; Azithromycin - therapeutic use; Bronchopulmonary Dysplasia - drug therapy; Bronchopulmonary Dysplasia - metabolism; Clinical Therapeutics; Cytokines - blood; Humans; Infant; Infant, Newborn; Infant, Premature; Inflammation - drug therapy; Inflammation - metabolism; Microbial Sensitivity Tests; Nonlinear Dynamics; Respiratory Tract Infections; Respiratory Tract Infections - drug therapy; Respiratory Tract Infections - microbiology; Treatment Outcome; Ureaplasma; Ureaplasma - drug effects; Ureaplasma - isolation & purification; Ureaplasma - pathogenicity; Ureaplasma Infections; Ureaplasma Infections - drug therapy
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/AAC.03951-14

The study objectives were to refine the population pharmacokinetics (PK) model, determine microbial clearance, and assess short-term pulmonary outcomes of multiple-dose azithromycin treatment in preterm infants at risk for Ureaplasma respiratory colonization. Fifteen subjects (7 of whom were Ureaplasma positive) received intravenous azithromycin at 20 mg/kg of body weight every 24 h for 3 doses. Azithromycin concentrations were determined in plasma samples obtained up to 168 h post-first dose by using a validated liquid chromatography-tandem mass spectrometry method. Respiratory samples were obtained predose and at three time points post-last dose for Ureaplasma culture, PCR, antibiotic susceptibility testing, and cytokine concentration determinations. Pharmacokinetic data from these 15 subjects as well as 25 additional subjects (who received either a single 10-mg/kg dose [n = 12] or a single 20-mg/kg dose [n = 13]) were analyzed by using a nonlinear mixed-effect population modeling (NONMEM) approach. Pulmonary outcomes were assessed at 36 weeks post-menstrual age and 6 months adjusted age. A 2-compartment model with all PK parameters allometrically scaled on body weight best described the azithromycin pharmacokinetics in preterm neonates. The population pharmacokinetics parameter estimates for clearance, central volume of distribution, intercompartmental clearance, and peripheral volume of distribution were 0.15 liters/h · kg(0.75), 1.88 liters · kg, 1.79 liters/h · kg(0.75), and 13 liters · kg, respectively. The estimated area under the concentration-time curve over 24 h (AUC24)/MIC90 value was ∼ 4 h. All posttreatment cultures were negative, and there were no drug-related adverse events. One Ureaplasma-positive infant died at 4 months of age, but no survivors were hospitalized for respiratory etiologies during the first 6 months (adjusted age). Thus, a 3-day course of 20 mg/kg/day intravenous azithromycin shows preliminary efficacy in eradicating Ureaplasma spp. from the preterm respiratory tract.